Publications by authors named "David B Shaw"

Claim this Profile
E
Effectiveness of the Veteran X peer-led mental health recovery program: A quasi-experimental study.
David B Shaw, N Sarah Magnes, Thomas E Pratt, Elizabeth Wetzler

Psychiatr Rehabil J· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and Pharmacological Characterization of C4-Amide-Substituted 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1 S,2 S,4 S,5 R,6 S)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2794193), a Highly Potent and Selective mGlu Receptor Agonist.
James A Monn, Steven S Henry, Steven M Massey, David K Clawson, Qi Chen, David B Shaw

J Med Chem· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist.
James A Monn, Lourdes Prieto, Lorena Taboada, Junliang Hao, Matthew R Reinhard, David B Shaw

J Med Chem· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and pharmacological characterization of C4-disubstituted analogs of 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: identification of a potent, selective metabotropic glutamate receptor agonist and determination of agonist-bound human mGlu2 and mGlu3 amino terminal domain structures.
James A Monn, Lourdes Prieto, Lorena Taboada, Concepcion Pedregal, Junliang Hao, David B Shaw

J Med Chem· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a novel series of orally active nociceptin/orphanin FQ (NOP) receptor antagonists based on a dihydrospiro(piperidine-4,7'-thieno[2,3-c]pyran) scaffold.
Miguel A Toledo, Concepción Pedregal, Celia Lafuente, Nuria Diaz, Maria Angeles Martinez-Grau, David B Shaw

J Med Chem· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
Linda M Rorick-Kehn, Jeffrey M Witkin, Michael A Statnick, Elizabeth L Eberle, Jamie H McKinzie, David B Shaw

Neuropharmacology· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The muscarinic acetylcholine receptor agonist BuTAC mediates antipsychotic-like effects via the M4 subtype.
Marla L Watt, Linda Rorick-Kehn, David B Shaw, Karen M Knitowski, Anne T Quets

Neuropsychopharmacology· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.
Katie Leach, Richard E Loiacono, Christian C Felder, David L McKinzie, Adrian Mogg, David B Shaw

Neuropsychopharmacology· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats.
Carrie K Jones, Elizabeth Lutz Eberle, David B Shaw, David L McKinzie, Harlan E Shannon

J Pharmacol Exp Ther· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis